Eli Lilly and Company is developing gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Our Clinical Trial for AK-antiVEGF:
The purpose of this trial is to evaluate whether the study drug, administered once using the study device, is safe at different dose levels. Researchers in this trial will also evaluate whether the study drug is able to stabilize or improve hearing and/or stop the growth of the tumor and/or shrink the size of the tumor in individuals affected by unilateral vestibular schwannoma.
For more information about our clinical trial and surgical administration procedure:
- AK-antiVEGF-101 | Vestibular Schwannoma Clinical Trial | Home
- Surgical Administration Procedure
- AK-antiVEGF-101 Clinical Trial Information Sheet
©2026 Lilly USA, LLC. All rights reserved.
